Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E.V. currently manages a patent portfolio with 2 pending office actions. These filings are categorized under the Biotechnology & Pharmaceuticals technology area. The prosecution is distributed across 2 distinct examiners and 2 distinct art units, which indicates that each pending action is being handled by a unique examiner in a unique art unit.
The busiest examiner for the portfolio is BRISTOL, LYNN ANNE, who is responsible for 1 busiest examiner pending office action. This single action assigned to BRISTOL, LYNN ANNE is part of the 2 total pending office actions currently tracked for the company. The ratio of actions to distinct examiners suggests a broad distribution of the legal workload across the patent office.
The involvement of the 2 distinct art units highlights that the portfolio's technical subject matter within Biotechnology & Pharmaceuticals is being reviewed by different specialized groups. Because there are 2 distinct examiners for the pending actions, the company is not currently facing a concentration of its matters under a single individual beyond the action assigned to the busiest examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §102 only | 1 (25%) |
| §112 only | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GOLDBERG, JEANINE ANNE | 1 | 45.4% | +40.5% |
| CHERNYSHEV, OLGA N | 1 | 54.5% | +34.0% |
| SHUPE, ELIZABETH A | 1 | 65.8% | +45.5% |
| CREWS, JARET JAMES | 1 | 43.9% | +71.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270409 | METHODS AND KITS FOR DETECTING A RISK FOR DEVELOPING NEUROLOGICAL OR NEUROPHYSIOLOGICAL DISORDERS | GOLDBERG, JEANINE ANNE | — |
| 17640119 | HERV INHIBITORS FOR USE IN TREATING TAUOPATHIES | CHERNYSHEV, OLGA N | — |
| 17627077 | NMDA RECEPTOR CONSTRUCTS TO DETECT AND ISOLATE NMDAR AUTOANTIBODIES | SHUPE, ELIZABETH A | — |
| 17263595 | POLYSIALIC ACID AND DERIVATIVES THEREOF, PHARMACEUTICAL COMPOSITION AND METHOD OF PRODUCING POLYSIALIC ACID | CREWS, JARET JAMES | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| 1675 | 1 |
| 1643 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18270409 | METHODS AND KITS FOR DETECTING A RISK FOR DEVELOPING NEUROLOGICAL OR NEUROPHYSIOLOGICAL DISORDERS | GOLDBERG, JEANINE ANNE | 1682 | §102 | Final Rejection | — | Pending | Jun 29, 2023 |
| 17640119 | HERV INHIBITORS FOR USE IN TREATING TAUOPATHIES | CHERNYSHEV, OLGA N | 1675 | §112 | Final Rejection | — | Pending | Mar 03, 2022 |
| 17627077 | NMDA RECEPTOR CONSTRUCTS TO DETECT AND ISOLATE NMDAR AUTOANTIBODIES | SHUPE, ELIZABETH A | 1643 | §103 | Final Rejection | — | Pending | Jan 13, 2022 |
| 17263595 | POLYSIALIC ACID AND DERIVATIVES THEREOF, PHARMACEUTICAL COMPOSITION AND METHOD OF PRODUCING POLYSIALIC ACID | CREWS, JARET JAMES | 1691 | §112 | Final Rejection | — | Pending | Jan 27, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E.V. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Jeanine Anne Goldberg has the most, with 1 of DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E.V.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
